PRO-BANTHINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRO-BANTHINE (PRO-BANTHINE).
Propantheline is a muscarinic receptor antagonist that competitively blocks the action of acetylcholine at postganglionic parasympathetic effector sites, resulting in anticholinergic effects such as decreased gastrointestinal motility and secretion.
| Metabolism | Primarily metabolized via hydrolysis to propantheline acid (xanthanoic acid derivative) and subsequent conjugation; CYP450 involvement is minimal. |
| Excretion | Renal excretion accounts for approximately 70% of elimination, with 30% as intact drug and 40% as inactive metabolites; biliary/fecal excretion contributes less than 5%. |
| Half-life | Terminal elimination half-life is approximately 9 hours (range 6-12 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment. |
| Protein binding | Propantheline is approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.5-1.0 L/kg, indicating extensive distribution into tissues, including the gastrointestinal tract. |
| Bioavailability | Oral bioavailability is low and variable, approximately 10-15% due to extensive first-pass metabolism; parenteral administration yields 100% bioavailability. |
| Onset of Action | Oral: 30-45 minutes; intravenous: 10-15 minutes; intramuscular: 20-30 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 4-6 hours; anticholinergic effects may persist longer due to active metabolites. |
15 mg orally three times daily before meals and 30 mg orally at bedtime.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: 15 mg orally twice daily; GFR <10 mL/min: 15 mg orally once daily. |
| Liver impairment | Child-Pugh Class B or C: 15 mg orally twice daily; monitor for adverse effects. |
| Pediatric use | 1.5 mg/kg/day orally divided every 6-8 hours; maximum 75 mg/day. |
| Geriatric use | Initial 7.5 mg orally three times daily before meals and 15 mg at bedtime; titrate cautiously due to increased anticholinergic sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRO-BANTHINE (PRO-BANTHINE).
| Breastfeeding | Excreted in human milk in very small amounts; M/P ratio: 0.5-1.0 (estimated). Consider benefits of breastfeeding, risk of infant exposure, and need for maternal therapy. Caution advised. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use only if clearly needed and potential benefit justifies potential risk to fetus. Trimesters: Insufficient data to quantify specific fetal risks by trimester. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning exists for propantheline.
| Serious Effects |
["Glaucoma (especially narrow-angle)","Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hyperplasia)","Myasthenia gravis","Gastrointestinal obstructive disease (e.g., pyloroduodenal stenosis)","Severe ulcerative colitis or toxic megacolon","Tachycardia or unstable cardiovascular status","Hypersensitivity to propantheline or any component of the formulation"]
| Precautions | ["Heat prostration can occur with use in hot environments due to suppressed sweating","May exacerbate glaucoma, urinary retention, and myasthenia gravis","Use cautiously in patients with autonomic neuropathy, hyperthyroidism, coronary artery disease, or hiatal hernia","May impair mental alertness (drowsiness, blurred vision)","Avoid in patients with GI obstruction or severe ulcerative colitis"] |
Loading safety data…
| Monitor maternal heart rate, blood pressure, and urinary output. Observe for anticholinergic effects (e.g., constipation, blurred vision, urinary retention). Fetal heart rate monitoring may be considered if signs of maternal toxicity. |
| Fertility Effects | Anticholinergic effects may impair fertility in males (erectile dysfunction) and females (vaginal dryness, altered cervical mucus). Reversible upon discontinuation. |